the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the anti-PD-1/anti-PD-L1 immunotherapy for lung cancer
After being informed of the study and potential risk, all patients giving written informed consent will undergo peripheral blood sample collection at baseline (before treatment ), 1month and 3month after treatment initiation, and when immune-related adverse events ever occur. The follow-up period will be 1 year for any occurrence of immune-related adverse events and 2 years follow-up for the prognosis.
Study Type
OBSERVATIONAL
Enrollment
120
Peking Union Medical College Hospital
Beijing, China
RECRUITINGoccurrence of immune-related adverse event (irAE)
Any adverse events occured within 12 months since immunotherapy initiation will be independently evaluated by two clinicians to determine whether it is irAE and all the clinical characteristics of irAE will be documented
Time frame: 12 months since immunotherapy initiation
Overall Survival
Patients will be followed up for 2 years to investigate Overall Survival
Time frame: 24 months since immunotherapy initiation
Progression Free Survival.
Patients will be followed up for 2 years to investigate Progression Free Survival.
Time frame: 24 months since immunotherapy initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.